BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 14645419)

  • 1. Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer.
    Gonzalez MA; Pinder SE; Callagy G; Vowler SL; Morris LS; Bird K; Bell JA; Laskey RA; Coleman N
    J Clin Oncol; 2003 Dec; 21(23):4306-13. PubMed ID: 14645419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression of MCM-2 in invasive breast carcinoma: a stereologic approach.
    Cobanoglu U; Mungan S; Gundogdu C; Ersoz S; Ozoran Y; Aydin F
    Bratisl Lek Listy; 2010; 111(1):45-9. PubMed ID: 20429312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of intensity of MT-I/II expression with Ki-67 and MCM-2 proteins in invasive ductal breast carcinoma.
    Wojnar A; Pula B; Piotrowska A; Jethon A; Kujawa K; Kobierzycki C; Rys J; Podhorska-Okolow M; Dziegiel P
    Anticancer Res; 2011 Sep; 31(9):3027-33. PubMed ID: 21868554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Minichromosome maintenance protein 2 expression in normal kidney and renal cell carcinomas: relationship to tumor dormancy and potential clinical utility.
    Rodins K; Cheale M; Coleman N; Fox SB
    Clin Cancer Res; 2002 Apr; 8(4):1075-81. PubMed ID: 11948116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer.
    Kim ST; Jeong H; Woo OH; Seo JH; Kim A; Lee ES; Shin SW; Kim YH; Kim JS; Park KH
    Am J Clin Oncol; 2013 Jun; 36(3):224-31. PubMed ID: 22495453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minichromosome maintenance proteins 2 and 5 expression in muscle-invasive urothelial cancer: a multivariate survival study including proliferation markers and cell cycle regulators.
    Korkolopoulou P; Givalos N; Saetta A; Goudopoulou A; Gakiopoulou H; Thymara I; Thomas-Tsagli E; Patsouris E
    Hum Pathol; 2005 Aug; 36(8):899-907. PubMed ID: 16112007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.
    Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I
    Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic values of proliferative markers ki-67 and repp86 in breast cancer.
    Mohsenifar J; Almassi-Aghdam M; Mohammad-Taheri Z; Zare K; Jafari B; Atri M; Mortazavi SH; Azadeh P; Bagherzadeh M; Azargashb E; Rahimi F
    Arch Iran Med; 2007 Jan; 10(1):27-31. PubMed ID: 17198450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between proliferation markers: PCNA, Ki-67, MCM-2 and antiapoptotic protein Bcl-2 in colorectal cancer.
    Guzińska-Ustymowicz K; Pryczynicz A; Kemona A; Czyzewska J
    Anticancer Res; 2009 Aug; 29(8):3049-52. PubMed ID: 19661314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic and molecular correlations of necrosis in the primary tumor of patients with renal cell carcinoma.
    Lam JS; Shvarts O; Said JW; Pantuck AJ; Seligson DB; Aldridge ME; Bui MH; Liu X; Horvath S; Figlin RA; Belldegrun AS
    Cancer; 2005 Jun; 103(12):2517-25. PubMed ID: 15880379
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of Mcm-2, Ki-67 and geminin in benign and malignant salivary gland tumours.
    Vargas PA; Cheng Y; Barrett AW; Craig GT; Speight PM
    J Oral Pathol Med; 2008 May; 37(5):309-18. PubMed ID: 18248354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of Ki-67 in chemotherapy-naive breast cancer patients with 10-year follow-up.
    Nishimiya H; Kosaka Y; Yamashita K; Minatani N; Kikuchi M; Ema A; Nakamura K; Waraya M; Sengoku N; Tanino H; Kuranami M; Watanabe M
    Anticancer Res; 2014 Jan; 34(1):259-68. PubMed ID: 24403472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new proliferation marker, minichromosome maintenance protein 2, is associated with tumor aggressiveness in esophageal squamous cell carcinoma.
    Kato H; Miyazaki T; Fukai Y; Nakajima M; Sohda M; Takita J; Masuda N; Fukuchi M; Manda R; Ojima H; Tsukada K; Asao T; Kuwano H
    J Surg Oncol; 2003 Sep; 84(1):24-30. PubMed ID: 12949987
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ki-67 MIB1 labelling index and the prognosis of primary TaT1 urothelial cell carcinoma of the bladder.
    Quintero A; Alvarez-Kindelan J; Luque RJ; Gonzalez-Campora R; Requena MJ; Montironi R; Lopez-Beltran A
    J Clin Pathol; 2006 Jan; 59(1):83-8. PubMed ID: 16394286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic values of osteopontin-c, E-cadherin and β-catenin in breast cancer.
    Pang H; Lu H; Song H; Meng Q; Zhao Y; Liu N; Lan F; Liu Y; Yan S; Dong X; Cai L
    Cancer Epidemiol; 2013 Dec; 37(6):985-92. PubMed ID: 24012693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of ghrelin is correlated to a favorable outcome in invasive breast cancer.
    Grönberg M; Fjällskog ML; Jirström K; Janson ET
    Acta Oncol; 2012 Mar; 51(3):386-93. PubMed ID: 22067021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of Ki-67 and MCM-2 proliferative marker expression with grade of histological malignancy (G) in ductal breast cancers.
    Wojnar A; Kobierzycki C; Krolicka A; Pula B; Podhorska-Okolow M; Dziegiel P
    Folia Histochem Cytobiol; 2010 Sep; 48(3):442-6. PubMed ID: 21097442
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of E2F-4 in invasive breast carcinomas is associated with poor prognosis.
    Rakha EA; Pinder SE; Paish EC; Robertson JF; Ellis IO
    J Pathol; 2004 Jul; 203(3):754-61. PubMed ID: 15221934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
    Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
    Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Geminin predicts adverse clinical outcome in breast cancer by reflecting cell-cycle progression.
    Gonzalez MA; Tachibana KE; Chin SF; Callagy G; Madine MA; Vowler SL; Pinder SE; Laskey RA; Coleman N
    J Pathol; 2004 Oct; 204(2):121-30. PubMed ID: 15376260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.